- $3.00bn
- $3.34bn
- $2.24bn
- 92
- 38
- 85
- 82
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 19.46 | ||
PEG Ratio (f) | 0.61 | ||
EPS Growth (f) | 47.21% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.76 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 33.09 | ||
Price to Sales | 1.33 | ||
EV to EBITDA | 52.23 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 2.47% | ||
Return on Equity | -1.9% | ||
Operating Margin | 1.76% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 1,955.63 | 2,071.52 | 2,214.11 | 2,223.2 | 2,236.38 | 2,321.49 | 2,453.91 | 6.11% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +19.35 | +18.43 | +35.33 | -42.06 | -35.63 | +79.31 | +9.73 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Amedisys, Inc. is a healthcare service company. The Company is engaged in providing care and support in the home. It delivers clinically distinct care that suits its patients' needs, whether that is home-based recovery and rehabilitation after an operation or injury or care. Its operations involve serving patients across the United States through its three operating divisions: home health, hospice, and high acuity care. Its home health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The home health includes 346 care centers located in 34 states within the United States and the District of Columbia. Its hospice care is designed to provide comfort and support for those who are dealing with a terminal illness. Its high acuity care segment delivers the essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes.
Directors
- Paul Kusserow CHM (59)
- Christopher Gerard PRE (54)
- Scott Ginn CFO (52)
- Sharon Brunecz CHO (54)
- Michael North CIO (56)
- Denise Bohnert CCO (43)
- David Kemmerly OTH (58)
- Richard Lechleiter LED (62)
- Vickie Capps IND (59)
- Molly Coye IND (73)
- Julie Klapstein IND (66)
- Teresa Kline IND (62)
- Bruce Perkins IND (67)
- Jeffrey Rideout IND (59)
- Ivanetta Samuels IND (52)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 28th, 1994
- Public Since
- August 17th, 1994
- No. of Shareholders
- 458
- No. of Employees
- 19,000
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 32,676,879
- Address
- 5959 S SHERWOOD FOREST BLVD, BATON ROUGE, 70816
- Web
- https://www.amedisys.com/
- Phone
- +1 2252922031
- Contact
- Nick Muscato
- Auditors
- KPMG LLP
Upcoming Events for AMED
Q2 2024 Amedisys Inc Earnings Release
Q3 2024 Amedisys Inc Earnings Release
Similar to AMED
23andMe Holding Co.
NASDAQ Global Select Market
Acadia Healthcare
NASDAQ Global Select Market
Accolade
NASDAQ Global Select Market
Addus HomeCare
NASDAQ Global Select Market
Alignment Healthcare
NASDAQ Global Select Market
FAQ
As of Today at 19:02 UTC, shares in Amedisys are trading at $91.79. This share price information is delayed by 15 minutes.
Shares in Amedisys last closed at $91.79 and the price had moved by +16.32% over the past 365 days. In terms of relative price strength the Amedisys share price has underperformed the S&P500 Index by -4.9% over the past year.
The overall consensus recommendation for Amedisys is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Amedisys does not currently pay a dividend.
Amedisys does not currently pay a dividend.
Amedisys does not currently pay a dividend.
To buy shares in Amedisys you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $91.79, shares in Amedisys had a market capitalisation of $3.00bn.
Here are the trading details for Amedisys:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AMED
Based on an overall assessment of its quality, value and momentum Amedisys is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Amedisys is $97.78. That is 6.53% above the last closing price of $91.79.
Analysts covering Amedisys currently have a consensus Earnings Per Share (EPS) forecast of $4.57 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amedisys. Over the past six months, its share price has underperformed the S&P500 Index by -17.96%.
As of the last closing price of $91.79, shares in Amedisys were trading -1.41% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Amedisys PE ratio based on its reported earnings over the past 12 months is 19.46. The shares last closed at $91.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Amedisys' management team is headed by:
- Paul Kusserow - CHM
- Christopher Gerard - PRE
- Scott Ginn - CFO
- Sharon Brunecz - CHO
- Michael North - CIO
- Denise Bohnert - CCO
- David Kemmerly - OTH
- Richard Lechleiter - LED
- Vickie Capps - IND
- Molly Coye - IND
- Julie Klapstein - IND
- Teresa Kline - IND
- Bruce Perkins - IND
- Jeffrey Rideout - IND
- Ivanetta Samuels - IND